Current Report Filing (8-k)
December 12 2019 - 9:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 12, 2019
OWC
Pharmaceutical Research Corp.
(Exact
Name of Registrant as Specified in its Charter)
Commission
File No.: 0-54856
Delaware
|
|
98-0573566
|
(State
of Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
|
|
|
2
Ben Gurion Street, Ramat Gan, Israel
|
|
4514760
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, including area code: 972 (0) 3-758-2657
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of each exchange on which registered
|
None
|
|
None
|
|
None
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Events.
OWC Pharmaceutical Research Corp. (“OWC”),
represented by its wholly-owned subsidiary, One World Cannabis Ltd., a company organized and existing under the laws of Israel
(“OWC-Israel”), announced that, on December 9, 2019, the United States Patent and Trademark Office issued a
Notice of Allowance indicating that OWC Israel’s Patent Application No. 15/629,230 directed to cannabis based extracts
and topical formulations for use in skin disorders, is allowed for issuance as a patent. The allowed patent application covers
the use of cannabis extracts in skin disorders, which is a key focus area for OWC’s clinical development program. OWC has
performed pre-clinical studies and has completed a human safety study with a cannabis-based ointment and is in the process of
procuring the necessary permits for an efficacy study on psoriatic patients.
This
allowed US patent application adds significantly to OWC’s intellectual property portfolio, which includes issued patents
for treatment of skin conditions in the Czech Republic and Australia, as well as other families of patent applications currently
under prosecution, directed to the use of cannabis-based extracts for further clinical indications and various non-clinical applications.
OWC believes that this topical ointment could offer relief for patients suffering from conditions such as Psoriatic lesions of
the face, which currently lack effective alternative topical treatments.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
OWC
PHARMACEUTICAL RESEARCH CORP.
|
|
|
|
|
By:
|
/s/ Mordechai
Bignitz
|
|
Name:
|
Mordechai
Bignitz
|
|
Title:
|
Chief
Executive Officer
|
|
|
|
Dated:
December 12, 2019
|
|
|
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Aug 2024 to Sep 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Sep 2023 to Sep 2024